Literature DB >> 9506488

Randomized, double-blind study on sedatives and hemodynamics during rapid-sequence intubation in the emergency department: The SHRED Study.

M L Sivilotti1, J Ducharme.   

Abstract

STUDY
OBJECTIVE: To compare thiopental, fentanyl, and midazolam for rapid-sequence induction and intubation (RSI).
METHODS: Eighty-six patients undergoing RSI in the emergency department were randomly assigned in a double-blind fashion to receive either thiopental (5 mg/kg), fentanyl (5 microg/kg), or midazolam (.1 mg/kg) before paralysis was induced. Outcome measures were mortality, speed and ease of intubation, and hemodynamics.
RESULTS: Of the patients who received thiopental, 93% were intubated within 2 minutes of paralysis (P=.037), but systolic blood pressure fell an average of 38 mm Hg in this group (P=.045). The midazolam group had a greater number of delayed intubations (31%) and an average heart rate increase of 17 beats/minute (P=.008). Mortality (24% inhospital) was unaffected by drug assignment. In all three groups, patients with pulmonary edema had the greatest decrease in blood pressure during RSI, and patients exposed to multiple attempts at intubation manifested pronounced hypertension.
CONCLUSION: Fentanyl provided the most neutral hemodynamic profile during RSI, although factors other than choice of sedative can play a more significant role in determining hemodynamic response. Depth of sedation may influence the speed of RSI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506488

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  9 in total

1.  Fentanyl is not best anaesthetic induction agent in rapid sequence intubation.

Authors:  I Taylor; D F Marsh
Journal:  BMJ       Date:  1998-11-14

2.  Prehospital rapid sequence induction by emergency physicians: is it safe?

Authors:  C A Mackay; J Terris; T J Coats
Journal:  Emerg Med J       Date:  2001-01       Impact factor: 2.740

Review 3.  Should etomidate be the induction agent of choice for rapid sequence intubation in the emergency department?

Authors:  A J Oglesby
Journal:  Emerg Med J       Date:  2004-11       Impact factor: 2.740

4.  Significant modification of traditional rapid sequence induction improves safety and effectiveness of pre-hospital trauma anaesthesia.

Authors:  Richard M Lyon; Zane B Perkins; Debamoy Chatterjee; David J Lockey; Malcolm Q Russell
Journal:  Crit Care       Date:  2015-04-01       Impact factor: 9.097

Review 5.  Intravenous hypnotic regimens in patients with liver disease; a review article.

Authors:  Hassan Soleimanpour; Saeid Safari; Farzad Rahmani; Asghar Jafari Rouhi; Seyed Moayed Alavian
Journal:  Anesth Pain Med       Date:  2015-02-24

Review 6.  Tracheal intubation in critically ill patients: a comprehensive systematic review of randomized trials.

Authors:  Luca Cabrini; Giovanni Landoni; Martina Baiardo Redaelli; Omar Saleh; Carmine D Votta; Evgeny Fominskiy; Alessandro Putzu; Cézar Daniel Snak de Souza; Massimo Antonelli; Rinaldo Bellomo; Paolo Pelosi; Alberto Zangrillo
Journal:  Crit Care       Date:  2018-01-20       Impact factor: 9.097

7.  A Comparison of the Effects of Dexmedetomidine and Propofol in Controlling the Hemodynamic Responses after Intubation: A Double-Blind, Randomized, Clinical Trial Study.

Authors:  Alireza Kamali; Mehrdad Taghizadeh; Mohtaram Esfandiar; Amin Shams Akhtari
Journal:  Open Access Maced J Med Sci       Date:  2018-11-10

Review 8.  Development of a standard operating procedure and checklist for rapid sequence induction in the critically ill.

Authors:  Peter Brendon Sherren; Stephen Tricklebank; Guy Glover
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2014-09-11       Impact factor: 2.953

9.  Incidence of and Risk Factors For Post-Intubation Hypotension in the Critically Ill.

Authors:  Nathan J Smischney; Onur Demirci; Daniel A Diedrich; David W Barbara; Benjamin J Sandefur; Sangita Trivedi; Sean McGarry; Rahul Kashyap
Journal:  Med Sci Monit       Date:  2016-02-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.